Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 12Other hematologic neoplasm 5Lymphoid 4Gastrointestinal 4Dermatologic 4Plasma cell 3Myeloid 2Tumor-Agnostic 1Thoracic 1Other 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Melanoma 4Skin Neoplasms 2

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19HhAntag691 19Mycophenolic Acid 18Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Tablets × Dermatologic × Clear all
NCT04722575 2025-03-13

NEO-TIM

Fondazione Melanoma Onlus

Phase 2 Active not recruiting
95 enrolled
Dermatologic

Melanoma

NCT05370807 2023-10-24

RegoMel

Universitair Ziekenhuis Brussel

Phase 2 Unknown
48 enrolled
Dermatologic

Melanoma

NCT00083239 2007-06-08

Study of Talabostat in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

NCT00083252 2007-06-08

Study of Talabostat and Cisplatin in Advanced Melanoma

Point Therapeutics

Phase 2 Completed
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡